Epigenetics in medullary thyroid cancer

From pathogenesis to targeted therapy

Erika Messina, C. Sciammarella, Antongiulio Faggiano, A. Colao

Research output: Contribution to journalArticle

Abstract

Background: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88-98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC. Objective: The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC. Methods: A systematic review was performed using Pubmed and Google patents databases. Results: We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field. Conclusion: Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.

Original languageEnglish
Pages (from-to)275-282
Number of pages8
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume11
Issue number3
Publication statusPublished - Aug 1 2016

Fingerprint

Epigenomics
Patents
Therapeutics
Histone Code
Mutation
Proto-Oncogenes
Germ-Line Mutation
DNA Methylation
MicroRNAs
PubMed
Genes
Medullary Thyroid cancer
Thyroid Gland
Databases
Pharmaceutical Preparations

Keywords

  • DNA methylation
  • Epigenetic therapy
  • Epigenetics
  • Histone modifications
  • Medullary thyroid cancer
  • MicroRNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)
  • Drug Discovery

Cite this

Messina, E., Sciammarella, C., Faggiano, A., & Colao, A. (2016). Epigenetics in medullary thyroid cancer: From pathogenesis to targeted therapy. Recent Patents on Anti-Cancer Drug Discovery, 11(3), 275-282.

Epigenetics in medullary thyroid cancer : From pathogenesis to targeted therapy. / Messina, Erika; Sciammarella, C.; Faggiano, Antongiulio; Colao, A.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, No. 3, 01.08.2016, p. 275-282.

Research output: Contribution to journalArticle

Messina, E, Sciammarella, C, Faggiano, A & Colao, A 2016, 'Epigenetics in medullary thyroid cancer: From pathogenesis to targeted therapy', Recent Patents on Anti-Cancer Drug Discovery, vol. 11, no. 3, pp. 275-282.
Messina, Erika ; Sciammarella, C. ; Faggiano, Antongiulio ; Colao, A. / Epigenetics in medullary thyroid cancer : From pathogenesis to targeted therapy. In: Recent Patents on Anti-Cancer Drug Discovery. 2016 ; Vol. 11, No. 3. pp. 275-282.
@article{5240a694ba4943cb8ce0ce1ee9487663,
title = "Epigenetics in medullary thyroid cancer: From pathogenesis to targeted therapy",
abstract = "Background: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88-98{\%} of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70{\%} of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC. Objective: The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC. Methods: A systematic review was performed using Pubmed and Google patents databases. Results: We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field. Conclusion: Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.",
keywords = "DNA methylation, Epigenetic therapy, Epigenetics, Histone modifications, Medullary thyroid cancer, MicroRNA",
author = "Erika Messina and C. Sciammarella and Antongiulio Faggiano and A. Colao",
year = "2016",
month = "8",
day = "1",
language = "English",
volume = "11",
pages = "275--282",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Epigenetics in medullary thyroid cancer

T2 - From pathogenesis to targeted therapy

AU - Messina, Erika

AU - Sciammarella, C.

AU - Faggiano, Antongiulio

AU - Colao, A.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88-98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC. Objective: The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC. Methods: A systematic review was performed using Pubmed and Google patents databases. Results: We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field. Conclusion: Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.

AB - Background: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88-98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC. Objective: The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC. Methods: A systematic review was performed using Pubmed and Google patents databases. Results: We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field. Conclusion: Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.

KW - DNA methylation

KW - Epigenetic therapy

KW - Epigenetics

KW - Histone modifications

KW - Medullary thyroid cancer

KW - MicroRNA

UR - http://www.scopus.com/inward/record.url?scp=84983770591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983770591&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 275

EP - 282

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 3

ER -